Use of tam receptor inhibitors as antimicrobials
AssigneeThe Salk Institute for Biological Studies
InventorsGreg E. Lemke, John A.T. Young, Carla V. Rothlin, Suchita Bhattacharyya
Life of this patent
Estimating the term…
Abstract
This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject.
Claims25
A method of enhancing a type I interferon (IFN) response against a pathogen in a subject, comprising:
- administering to a subject infected with a pathogen a therapeutically effective amount of a TAM receptor inhibitor, thereby enhancing the type I interferon response against a pathogen in the subject.
(canceled)
(canceled)
-15. (canceled)
(canceled)
A method of treating a viral or bacterial infection in a subject, comprising:
- administering to a subject infected with a virus or bacteria a therapeutically effective amount of a TAM receptor inhibitor, thereby treating the viral or bacterial infection.
A method of screening for an antimicrobial agent, comprising:
- contacting a cell expressing a TAM receptor with a test agent;
- contacting the cell with a pathogen;
- and
- measuring IFN-beta (IFN-β) production or IFN-alpha (IFN-α) production by the cell, wherein an increase in IFN-β or IFN-α production by the cell indicates that the test agent is an antimicrobial agent.
-30. (canceled)
Dependencies are inferred from the claim text.